Zenas biopharma, inc.ZBIO.US Overview
ZBIO Overall Performance
ZBIO AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
ZBIO Current Performance
1.42%
Zenas biopharma, inc.
2.97%
Avg of Sector
1.52%
S&P500
ZBIO Key Information
ZBIO Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
ZBIO Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
ZBIO Profile
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.
Price of ZBIO
ZBIO FAQ
When is ZBIO's latest earnings report released?
The most recent financial report for Zenas biopharma, inc. (ZBIO) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ZBIO's short-term business performance and financial health. For the latest updates on ZBIO's earnings releases, visit this page regularly.
How much debt does ZBIO have?
As of the end of the reporting period, Zenas biopharma, inc. (ZBIO) had total debt of 1.01M, with a debt ratio of 0. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does ZBIO have?
At the end of the period, Zenas biopharma, inc. (ZBIO) held Total Cash and Cash Equivalents of 44.01M, accounting for 0.15 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is ZBIO's EPS continuing to grow?
According to the past four quarterly reports, Zenas biopharma, inc. (ZBIO)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.25. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of ZBIO?
Zenas biopharma, inc. (ZBIO)'s Free Cash Flow (FCF) for the period is -41.74M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 34.68% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of ZBIO?
The latest valuation data shows Zenas biopharma, inc. (ZBIO) has a Price-To-Earnings (PE) ratio of -3.78 and a Price/Earnings-To-Growth (PEG) ratio of -0.03. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.